Cardiovascular risk assessment has long centered on cholesterol, blood pressure, and glucose — but mounting evidence suggests that what happens during the night hours may be just as consequential as any of these traditional markers. A sweeping review of research published between mid-2024 and early 2026 consolidates findings across sleep science and cardiology into a clinically actionable picture that challenges practitioners to treat sleep as a primary, not secondary, risk variable.
The review, published in Current Opinion in Cardiology, synthesizes evidence from a field that now counts over one billion adults globally as having clinically significant sleep disorders. Obstructive sleep apnea (OSA) emerges as an independent predictor of major adverse cardiovascular events, with nocturnal hypoxemia — periods of low blood oxygen during sleep — identified as a particularly important marker for risk stratification. Continuous positive airway pressure (CPAP) therapy was associated with reduced cardiovascular complications, though notably in carefully selected, higher-risk OSA patients rather than broadly across all diagnoses. Irregular sleep timing and insufficient duration were independently linked to arrhythmias and cardiac failure. Mechanistically, the review highlights oxidative stress and autonomic nervous system dysregulation as core drivers of adverse cardiac remodeling from sleep disruption, and Mendelian randomization genetic studies add causal weight to the OSA–coronary artery disease association.
This review carries real clinical weight for several reasons. First, the American Heart Association's formal incorporation of sleep into its Life's Essential 8 framework signals institutional recognition that sleep deprivation belongs alongside smoking and hypertension as a modifiable cardiac risk factor. Second, the mechanistic specificity — oxidative stress pathways and autonomic dysfunction — opens therapeutic targets beyond CPAP. However, this is a narrative review rather than a meta-analysis, and many underlying studies remain observational. The CPAP benefit finding remains nuanced; previous large randomized trials like SAVE and ISAACC showed limited cardiovascular benefit in unselected OSA populations, suggesting patient phenotyping is essential. For health-conscious adults, the aggregate message is clear: sleep quality, duration, and regularity are now firmly inside the cardiovascular risk conversation.
